Catalase-like metal–organic framework nanoparticles to enhance radiotherapy in hypoxic cancer and prevent cancer recurrence

Chen, Yuanyuan; Hui, Zhong; Wang, Jianbo; Wan, Xiuyan; Li, Yanhua; Pan, Wei; Li, Na; Tang, Bo

doi:10.1039/c9sc00747d

Cited by 131 publications

(105 citation statements)

References 38 publications

Supporting

Mentioning

104

Contrasting

Order By: Relevance

“…28 Furthermore, manganese porphyrin with catalase activity enhances RT through the catalytic decomposition of endogenous H 2 O 2 to O 2 . 29,30 Then, the potential multifunctional characteristics of FA-Hf-Mn-NMOF (fHMNM) were explored both qualitatively and quantitatively in vitro and in vivo.…”

Section: Introductionmentioning

confidence: 99%

<p>Multifunctional Hf/Mn-TCPP Metal-Organic Framework Nanoparticles for Triple-Modality Imaging-Guided PTT/RT Synergistic Cancer Therapy</p>

Bao¹,

Zu²,

Wang³

et al. 2020

IJN

View full text Add to dashboard Cite

Background: Recent studies have validated and confirmed the great potential of nanoscale metal-organic framework (NMOF) in the biomedical field, especially in improving the efficiency of cancer diagnosis and therapy. However, most previous studies only utilized either the metal cluster or the organic ligand of the NMOF for cancer treatments and merely reported limited theranostic functions, which may not be optimized. As a highly designable and easily functionalized material, prospective rational design offers a powerful way to extract the maximum benefit from NMOF for cancer theranostic applications. Materials and Methods: A NMOF based on hafnium (Hf) cluster and Mn(III)-porphyrin ligand was rational designed and synthesized as a high-performance multifunctional theranostic agent. The folic acid (FA) was modified on the NMOF surface to enhance the cancer targeting efficacy. The proposed "all-in-one" FA-Hf-Mn-NMOF (fHMNM) was characterized and identified using various analytical techniques. Then, in vitro and in vivo studies were performed to further explore the effects of fHMNM both as the magnetic resonance imaging (MRI)/computed tomography (CT)/photoacoustic imaging (PAI) contrast agent and as the photothermal therapy (PTT)/radiotherapy (RT) agent. Results: A tumour targeting multifunctional fHMNM was successfully synthesized with high performance for MRI/CT/PAI enhancements and image-guided PTT/RT synergistic therapy properties. Compared with the current clinical CT and MR contrast agents, the X-ray attenuation and T 1 relaxation rate of this integrated nanosystem increased 1.7-fold and 3-5-fold, respectively. More importantly, the catalase-like Mn(III)-porphyrin ligand can decompose H 2 O 2 into O 2 in tumour microenvironments to improve the synergistic treatment efficiency of PTT and RT. Significant tumour growth inhibition was achieved in mouse cancer models without obvious damage to the other organs. Conclusion: This work highlights the potential of fHMNM as an easily designable material for biomedical applications, could be an effective tool for in vivo detection and subsequent treatment of tumour.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>Multifunctional Hf/Mn-TCPP Metal-Organic Framework Nanoparticles for Triple-Modality Imaging-Guided PTT/RT Synergistic Cancer Therapy</p>

Bao¹,

Zu²,

Wang³

et al. 2020

IJN

View full text Add to dashboard Cite

show abstract

“…Another major obstacle for improving the anticancer efficacy of RT is the hypoxic microenvironment found in many advanced tumors. 51,52 Tumor hypoxia results from insufficient and heterogeneous blood supply to deeply seated tumors, promoting local tumor progression and systemic metastasis as well as compromising the efficacy of many anticancer treatments, particularly RT. 6 In the absence of oxygen, radiationinduced radicals can abstract hydrogen atom from nonprotein sulydryls and lose the ability to cause DNA damage, leading to hypoxia-induced radiation resistance.…”

Section: Discussionmentioning

confidence: 99%

“…In particular, HIF1-a has been shown to drive the expression of PD-L1, helping the tumors to resist cytotoxic T-cell therapy. 51 The upregulation of HIF1-a signaling also promotes the enzymatic activity of CD73, an ectonucleotidase that converts extracellular adenosine triphosphate to adenosine. 54 The accumulation of adenosine hampers the activation of antitumor immunity through many different pathways.…”

Section: Discussionmentioning

confidence: 99%

Biomimetic nanoscale metal–organic framework harnesses hypoxia for effective cancer radiotherapy and immunotherapy

Lan

Song

et al. 2020

Chem. Sci.

View full text Add to dashboard Cite

show abstract

Section: Catalytic Proteins With Noncytotoxicity As Adjuvant Agentsmentioning

confidence: 99%

“…In another study (Figure 6C), Chen et al developed a hafnium‐involved manganoporphyrin metal‐organic framework (MOF) to implement hypoxia relief (with catalase‐like manganese ions) and enhanced radiotherapy (with a hafnium cluster‐based radiosensitizer). [ 77 ] Zhen et al [ 78 ] conducted one‐step biomineralization of BSA‐iridium oxide hybrid nanoparticles (BSA‐IrO 2 ). As shown in Figure 6D, this simple integration enabled the multiple functions of photoacoustic, computed tomography, and thermal imaging, photothermal conversion, and photocatalytic activities.…”

Section: Catalytic Proteins With Noncytotoxicity As Adjuvant Agentsmentioning

confidence: 99%

Protein‐Based Artificial Nanosystems in Cancer Therapy

Zhang

Mei

Guan

et al. 2020

Small

View full text Add to dashboard Cite

Proteins, like actors, play different roles in specific applications. In the past decade, significant achievements have been made in protein‐engineered biomedicine for cancer therapy. Certain proteins such as human serum albumin, working as carriers for drug/photosensitizer delivery, have entered clinical use due to their long half‐life, biocompatibility, biodegradability, and inherent nonimmunogenicity. Proteins with catalytic abilities are promising as adjuvant agents for other therapeutic modalities or as anticancer drugs themselves. These catalytic proteins are usually defined as enzymes with high biological activity and substrate specificity. However, clinical applications of these kinds of proteins remain rare due to protease‐induced denaturation and weak cellular permeability. Based on the characteristics of different proteins, tailor‐made protein‐based nanosystems could make up for their individual deficiencies. Therefore, elaborately designed protein‐based nanosystems, where proteins serve as drug carriers, adjuvant agents, or therapeutic drugs to make full use of their intrinsic advantages in cancer therapy, are reviewed. Up‐to‐date progress on research in the field of protein‐based nanomedicine is provided.

show abstract

Catalase-like metal–organic framework nanoparticles to enhance radiotherapy in hypoxic cancer and prevent cancer recurrence

Abstract: Tumor hypoxia typically occurs inside a solid tumor with an inadequate oxygen supply, sharply reducing the therapeutic efficiency of radiotherapy and significantly increasing the risk of local tumor recurrence.

Cited by 131 publications

References 38 publications

<p>Multifunctional Hf/Mn-TCPP Metal-Organic Framework Nanoparticles for Triple-Modality Imaging-Guided PTT/RT Synergistic Cancer Therapy</p>

<p>Multifunctional Hf/Mn-TCPP Metal-Organic Framework Nanoparticles for Triple-Modality Imaging-Guided PTT/RT Synergistic Cancer Therapy</p>

Biomimetic nanoscale metal–organic framework harnesses hypoxia for effective cancer radiotherapy and immunotherapy

Protein‐Based Artificial Nanosystems in Cancer Therapy

Contact Info

Product

Resources

About